Key Points
- Insulet director Timothy Stonesifer bought 2,790 shares on June 3 at an average price of $143.51, spending $400,392.90 and increasing his ownership by 44.63% to 9,041 shares.
- Insulet recently reported strong quarterly results, with EPS of $1.42 versus estimates of $1.19 and revenue of $761.7 million, up 33.9% year over year.
- Wall Street remains cautiously positive on the stock: analysts have a consensus rating of “Moderate Buy” with an average price target of $252.04, though several firms have recently cut targets.
Insulet Corporation (NASDAQ:PODD - Get Free Report) Director Timothy Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company's stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Insulet Price Performance
NASDAQ PODD opened at $146.41 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The company has a market capitalization of $10.14 billion, a PE ratio of 34.05, a price-to-earnings-growth ratio of 1.13 and a beta of 1.13. The firm's 50 day moving average is $176.99 and its 200-day moving average is $239.50.
Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period last year, the company earned $1.02 earnings per share. The firm's revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Insulet
Several institutional investors and hedge funds have recently modified their holdings of the stock. Avidity Partners Management LP acquired a new position in shares of Insulet in the first quarter valued at $2,098,000. Glenmede Trust Co. NA increased its holdings in shares of Insulet by 6.5% in the first quarter. Glenmede Trust Co. NA now owns 2,717 shares of the medical instruments supplier's stock valued at $570,000 after purchasing an additional 166 shares during the last quarter. Essential Partners LLC increased its holdings in shares of Insulet by 9,980.0% in the first quarter. Essential Partners LLC now owns 504 shares of the medical instruments supplier's stock valued at $106,000 after purchasing an additional 499 shares during the last quarter. Western Wealth Management LLC acquired a new position in shares of Insulet in the first quarter valued at $80,000. Finally, Edgestream Partners L.P. increased its holdings in shares of Insulet by 131.1% in the first quarter. Edgestream Partners L.P. now owns 21,645 shares of the medical instruments supplier's stock valued at $4,542,000 after purchasing an additional 12,277 shares during the last quarter.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Stifel Nicolaus lowered their target price on shares of Insulet from $350.00 to $250.00 in a report on Thursday, May 7th. BTIG Research lowered their target price on shares of Insulet from $260.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, May 26th. William Blair assumed coverage on shares of Insulet in a report on Wednesday, May 20th. They set an "outperform" rating on the stock. Barclays lowered their target price on shares of Insulet from $286.00 to $198.00 and set an "underweight" rating on the stock in a report on Thursday, May 7th. Finally, Wells Fargo & Company lowered their target price on shares of Insulet from $360.00 to $255.00 and set an "overweight" rating on the stock in a report on Wednesday, May 6th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $252.04.
Check Out Our Latest Report on PODD
About Insulet
(
Get Free Report)
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
